OptiKira Pursuing A Novel Small-Molecule Approach To Retinitis Pigmentosa

 
• By John Davis

An early-stage, small-molecule approach to the treatment of retinitis pigmentosa being developed by US biotech OptiKira may have potential benefits over more advanced gene and cell therapies for the blindness-causing condition.

Vision

More from Sensory

More from Therapy Areas